These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 28365530)

  • 1. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab.
    Hauschild A; Eichstaedt J; Möbus L; Kähler K; Weichenthal M; Schwarz T; Weidinger S
    Eur J Cancer; 2017 May; 77():84-87. PubMed ID: 28365530
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature.
    Deinlein T; Lax SF; Schwarz T; Giuffrida R; Schmid-Zalaudek K; Zalaudek I
    Eur J Cancer; 2017 Sep; 83():99-102. PubMed ID: 28734147
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum.
    Salomon G; Maza A; Boulinguez S; Paul C; Lamant L; Tournier E; Mazereeuw-Hautier J; Meyer N
    Br J Dermatol; 2018 May; 178(5):1199-1203. PubMed ID: 29274233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.
    Thiem A; Kneitz H; Schummer P; Herz S; Schrama D; Houben R; Goebeler M; Schilling B; Gesierich A
    Acta Derm Venereol; 2017 Nov; 97(10):1252-1254. PubMed ID: 28761962
    [No Abstract]   [Full Text] [Related]  

  • 5. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
    Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
    Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
    [No Abstract]   [Full Text] [Related]  

  • 6. A rapid response to pembrolizumab in a patient with metastatic melanoma.
    Bayo Calero J; Aviñó Tarazona V
    Immunotherapy; 2017 Mar; 9(3):225-228. PubMed ID: 28231724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.
    Maul LV; Weichenthal M; Kähler KC; Hauschild A
    J Immunother; 2016 May; 39(4):188-90. PubMed ID: 27023060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to PD-1 blockade in melanoma.
    Burki TK
    Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
    [No Abstract]   [Full Text] [Related]  

  • 9. Pembrolizumab for the treatment of melanoma.
    Kumar SS; McNeil CM
    Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.
    Hwang SJ; Carlos G; Chou S; Wakade D; Carlino MS; Fernandez-Penas P
    Melanoma Res; 2016 Aug; 26(4):413-6. PubMed ID: 27031539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition.
    Harvey NT; Millward M; Macgregor K; Bucat RP; Wood BA
    Am J Dermatopathol; 2016 Dec; 38(12):e159-e162. PubMed ID: 27870733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immune checkpoint antibodies increase survival in patients with metastatic melanoma].
    Fløe LE; Svane IM; Bastholt L; Schmidt H
    Ugeskr Laeger; 2016 Aug; 178(33):. PubMed ID: 27550784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of long-term follow-up in xeroderma pigmentosum.
    Min JA; Lee JY; Cho BK; Park HJ
    Int J Dermatol; 2010 Jun; 49(6):720-2. PubMed ID: 20618485
    [No Abstract]   [Full Text] [Related]  

  • 14. Dramatic response to nivolumab in xeroderma pigmentosum skin tumor.
    Chambon F; Osdoit S; Bagny K; Moro A; Nguyen J; Réguerre Y
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28988442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient.
    Kilickap S; Guven DC; Aktepe OH; Aktas BY; Dizdar O
    J Oncol Pharm Pract; 2020 Mar; 26(2):496-499. PubMed ID: 31256744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of pembrolizumab-induced localized organizing pneumonia.
    Arays R; Wang P
    Scand J Immunol; 2018 Jul; 88(1):e12677. PubMed ID: 29856074
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of pembrolizumab in a patient with xeroderma pigmentosum variant and advanced cutaneous squamous-cell carcinoma.
    Hennemann A; Collonge Rame MA; Puzenat E; Ged C; Harbon S; Aubin F; Nardin C
    Acta Oncol; 2022 Sep; 61(9):1140-1142. PubMed ID: 35950634
    [No Abstract]   [Full Text] [Related]  

  • 18. Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia.
    Arenbergerova M; Fialova A; Arenberger P; Gkalpakiotis S; Jirasek T; Srp A; Novotna A; Frankova H
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):e72-e74. PubMed ID: 28833722
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
    Longoria TC; Tewari KS
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xeroderma pigmentosum variant or pigmented xerodermoid.
    Somos S; Schneider I; Raskó I
    Anticancer Res; 1997; 17(1B):753-6. PubMed ID: 9066615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.